[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"National Institute of Respiratory Diseases, Mexico\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":135},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,4,0,[8,47,79,105],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":18,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":29,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":35,"lastUpdatePostDateStruct":36,"startDateStruct":39,"completionDateStruct":41,"leadSponsor":43,"locationsCount":46},"100560038","phase-4-effect-of-the-inhaled-triple-therapies-over-the-small-airway-in-biomass-exposure-100560038",false,"NCT06571942","Effect of the Inhaled Triple Therapies Over the Small Airway in Biomass Exposure","Effect of the Inhaled Triple Therapies Over the Small Airway in Patients With Chronic Obstructive Pulmonary Disease or Chronic Bronchitis Without Obstruction Secondary to Biomass Exposure: Randomized Controlled Clinical Trial Phase IV","Inclusion Criteria:\n\n* Subject capable of understanding instructions and giving her consent for participation.\n* Diagnosis of COPD or chronic bronchitis without obstruction due to biomass smoke exposure:\n\n  1. Diagnosis of COPD according to GOLD guidelines 2023 with: \\>100 hours-year of biomass exposure index, and with a post-bronchodilator spirometry FEV1 \\> 70% of predicted value.\n  2. Diagnosis of Chronic Bronchitis without obstruction with at least \\>100 hours-year of biomass smoke exposure index or more than 10 years of continued exposure to biomass smoke, and with 1) antecedent of chronic bronchitis, and 2) post-bronchodilator spirometry FEV1\u002FFVC \\>0.7.\n* Able to attend all visits.\n* Cooperative patients with adequate understanding and skill in using inhalers, or with caregivers capable of administering medications and filling out a daily symptom diary.\n* Stable patients, with no history of exacerbations in the last 4 weeks before inclusion.\n\nExclusion Criteria:\n\n* Pregnancy or in the breastfeeding period.\n* Documented allergy or intolerance to any of the study medications.\n* History of clinically significant bronchiectasis, tuberculosis, recent respiratory infection (4 weeks), or cardiovascular comorbidity that contraindicates pulmonary function tests or that influences their status and functional class.\n* Patients with suspicion or history of cancer.\n* Uncontrolled diseases: acute hyperthyroidism, acute uncontrolled DM2, acid-peptic disease that causes bleeding, uncontrolled hematological diseases, etc. In general, any decompensated disease that, in the opinion of the principal investigator, may influence the results of the study.","FEMALE","35 Years","85 Years",{"count":20,"type":21},128,"ESTIMATED","INTERVENTIONAL",[24],"PHASE4","This phase IV randomized controlled clinical trial intend to compare the effect of three close standard inhaled triple therapies and one close standard inhaled double therapy on the small airway in patients with Chronic Obstructive Pulmonary Disease (COPD-B) and chronic bronchitis without obstruction (BCNO) exposed to wood smoke. The treatment phase duration is of 3 months. As primary outcome, the resistance change in post-bronchodilatator impulse oscilometry will me measure at 30 minutes, 2 hours, 4 hours, and 24 hours post first dose of the asigned medication, and then at 1 and 3 months of treatment. As secondary outcomes, change in respiratory symptoms and health related quality of life will be assess after 1 and 3 months of treatment.",[27,28],"COPD Bronchitis","Pollution Related Respiratory Disorder",[30,31,32,33],"Biomass","COPD","Chronic bronchitis","Inhaled therapy","RECRUITING","2024-08-25",{"date":37,"type":38},"2024-08-26","ACTUAL",{"date":40,"type":38},"2023-11-15",{"date":42,"type":21},"2025-01-15",{"name":44,"class":45},"National Institute of Respiratory Diseases, Mexico","OTHER_GOV",1,{"id":48,"slug":49,"hasResults":11,"nctId":50,"briefTitle":51,"officialTitle":52,"acronym":4,"eligibilityCriteria":53,"healthyVolunteers":11,"sex":54,"minAge":55,"maxAge":4,"enrollmentInfo":56,"targetDuration":4,"studyType":22,"phases":58,"briefSummary":60,"conditions":61,"keywords":64,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":71,"lastUpdatePostDateStruct":72,"startDateStruct":74,"completionDateStruct":76,"leadSponsor":78,"locationsCount":46},"100556926","nutritional-therapy-enriched-with-omega-3-in-patients-with-lung-resection-100556926","NCT06531460","Nutritional Therapy Enriched With Omega-3 in Patients With Lung Resection","Effect of Perioperative Nutrition Enriched With Omega-3 on the Incidence of Infections in Oncologic Patients Following Lung Resection","Inclusion Criteria:\n\n* Lung cancer diagnosis\n* Elective surgery for lung resection schedule at least four days before surgery\n* Signed informed consent.\n\nExclusion Criteria:\n\n* Acute or chronic organ failure as hepatic or renal insufficiency\n* Patients with fish-allergy\n* History of any surgery within 3 months\n* Immunocompromised patients","ALL","18 Years",{"count":57,"type":21},310,[59],"NA","The aim of this study is to analyze the effect of enriched formula with omega-3 in the 30-day incidence infection and inflammatory response following lung resection surgery in lung cancer patients.",[62,63],"Lung Cancer","Surgery",[65,66,67,68,69,70],"lung cancer","omega-3","prehabilitation nutrition","perioperative nutrition","infections","inflammation response","2024-07-29",{"date":73,"type":38},"2024-08-01",{"date":75,"type":38},"2024-07-25",{"date":77,"type":21},"2027-07",{"name":44,"class":45},{"id":80,"slug":81,"hasResults":11,"nctId":82,"briefTitle":83,"officialTitle":84,"acronym":4,"eligibilityCriteria":85,"healthyVolunteers":11,"sex":54,"minAge":55,"maxAge":4,"enrollmentInfo":86,"targetDuration":4,"studyType":22,"phases":87,"briefSummary":88,"conditions":89,"keywords":91,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":97,"lastUpdatePostDateStruct":98,"startDateStruct":100,"completionDateStruct":102,"leadSponsor":104,"locationsCount":46},"100555376","nutritional-therapy-in-patients-with-post-extubation-dysphagia-100555376","NCT06511284","Nutritional Therapy in Patients With Post-extubation Dysphagia","Swallowing and Nutritional Therapy and Its Impact on Body Composition and Clinical Outcomes in Patients With Post-extubation Dysphagia","Inclusion Criteria:\n\n* Patients who required invasive mechanical ventilation during their hospital stay with a diagnosis of post-extubation dysphagia diagnosed by fibroendoscopy evaluation of swallowing (FEES).\n* Patients who discharged with a feeding tube.\n* Patients with signed informed consent.\n\nExclusion Criteria:\n\n* Patients with pre-existing dysphagia, or with neurological conditions that can cause dysphagia (e.g. multiple sclerosis, Parkinson's disease, Alzheimer's, myasthenia gravis).\n* Patients with chronic kidney disease, defined as a glomerular filtration rate \\\u003C60 ml\u002Fmin.\n* Patients discharged with a terminal condition and\u002For life expectancy of less than 3 months.\n* Diagnosis of HIV, upon receiving clinical follow-up by the team of specialists.",{"count":20,"type":21},[59],"The aim of this study is to evaluate the impact of the prescription of two doses of protein on the amount in kilograms of muscle mass and on the clinical evolution (time until safe swallowing, time until removal of the feeding stoma, number of hospital readmissions, feeding stoma infections, incidence of pneumonia, functionality, number of falls, fractures and mortality) at 6 months after hospital discharge in patients with enteral nutrition due to post-extubation dysphagia.",[90],"Dysphagia",[92,93,94,95,96],"enteral nutrition","nutritional assessment","nutritional therapy","Deglutition Disorders","rehabilitation","2024-07-15",{"date":99,"type":38},"2024-07-19",{"date":101,"type":38},"2024-07-01",{"date":103,"type":21},"2027-12-01",{"name":44,"class":45},{"id":106,"slug":107,"hasResults":11,"nctId":108,"briefTitle":109,"officialTitle":110,"acronym":4,"eligibilityCriteria":111,"healthyVolunteers":11,"sex":54,"minAge":55,"maxAge":4,"enrollmentInfo":112,"targetDuration":4,"studyType":22,"phases":114,"briefSummary":115,"conditions":116,"keywords":122,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":127,"lastUpdatePostDateStruct":128,"startDateStruct":130,"completionDateStruct":132,"leadSponsor":134,"locationsCount":46},"100535605","phase-4-effectiveness-of-combined-tobacco-treatment-in-hospitalized-subjects-100535605","NCT06254001","Effectiveness of Combined Tobacco Treatment in Hospitalized Subjects","Effectiveness of Combined Treatment of Bupropion and Nicotine Replacement Therapy in Hospitalized Subjects With Active Smoking in a Reference Center","Inclusion Criteria:\n\n\\>18 years Active smokers (consumption of more than 100 cigarettes in their entire life, and who have consumed cigarettes in the last 30 days) Hospitalized subjects Informed consent\n\nExclusion Criteria:\n\n* Subjects who have had pharmacological treatment to stop smoking in the last month\n* Subjects with contraindications for medications.\n\nSample size calculation, 80% power, unilateral, due to difference in proportions, estimated loss of 25%.",{"count":113,"type":21},134,[24],"In the 20th century, tobacco caused the death of 100 million people worldwide and it is estimated that it will be responsible for 1 billion deaths in the 21st century. Currently 8 million people die each year from smoking, 7 million are associated with active smoking, thus being the main risk factor for loss of disability-adjusted life years for men and the ninth most important risk factor for women. In previous studies it has been reported that approximately 21% (14%-30%) of subjects who have required hospitalization are active smokers, being higher in men than in women (28% vs 14%). The initiation of treatment for smoking cessation in this group of subjects has shown an effectiveness rate of up to 65% to maintain abstinence 6 to 12 months after discharge. The effectiveness has been analyzed in scenarios with only brief advice, in some others with the use of medications such as varenicline, bupropion and nicotine replacement therapy, however, the interventions have not been standardized for adequate analysis, which could contribute to the different results.",[117,118,119,120,121],"Tobacco Smoking","Tobacco Withdrawal","Nicotine Addiction","Nicotine Withdrawal","Nicotine Replacement Therapy",[123,124,125,126],"tobacco","bupropion","nicotine replacement therapy","abstinence","2024-02-21",{"date":129,"type":38},"2024-02-23",{"date":131,"type":38},"2024-01-15",{"date":133,"type":21},"2026-06-15",{"name":44,"class":45},""]